An integrated approach for obesity management: the effectiveness of glucagon-like peptide 1 agonist and life-style interventions for obesity management
Background. The obesity is found in 24.8 % (approximately 10 million people) and overweight in 34.3 % of the population of Ukraine, mainly in females. Obesity is associated with hereditary factors, overeating as well as a sedentary lifestyle. An integrated approach is applied to treat obesity such a...
Main Authors: | A.V. Dinets, M.B. Gorobeiko, V.V. Zdorna, V.H. Hoperia, A.V. Lovin |
---|---|
Format: | Article |
Language: | English |
Published: |
Zaslavsky O.Yu.
2022-05-01
|
Series: | Mìžnarodnij Endokrinologìčnij Žurnal |
Subjects: | |
Online Access: | https://iej.zaslavsky.com.ua/index.php/journal/article/view/1161 |
Similar Items
-
Positive effect of vitamin D supplementation on weight loss in obese patients treated with glucagon-like peptide 1 and lifestyle interventions
by: M.B. Gorobeiko, et al.
Published: (2022-09-01) -
Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity
by: Ekaterina V. Tikhonenko, et al.
Published: (2018-12-01) -
First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis
by: Rui Deng, et al.
Published: (2024-01-01) -
The advisory board resolution on the use of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes
by: M. B. Antsiferov, et al.
Published: (2023-05-01) -
An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism
by: Ren Q, et al.
Published: (2022-10-01)